Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Ninety One SA PTY Ltd

Ninety One SA PTY Ltd trimmed its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 29.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 53,096 shares of the medical research company’s stock after selling 22,422 shares during the period. Ninety One SA PTY Ltd’s holdings in Edwards Lifesciences were worth $3,931,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of EW. Wellington Management Group LLP grew its holdings in Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after purchasing an additional 14,610,123 shares during the last quarter. Jennison Associates LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $555,939,000. Assenagon Asset Management S.A. grew its stake in Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after acquiring an additional 3,506,886 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Edwards Lifesciences by 239.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after acquiring an additional 2,606,950 shares in the last quarter. Finally, Seilern Investment Management Ltd acquired a new position in Edwards Lifesciences during the fourth quarter worth about $109,490,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

EW opened at $71.33 on Wednesday. The company has a 50 day moving average of $72.49 and a two-hundred day moving average of $69.63. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $42.07 billion, a P/E ratio of 10.29, a P/E/G ratio of 3.72 and a beta of 1.11.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 8,000 shares of company stock worth $547,430. Corporate insiders own 1.27% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on EW. Barclays increased their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, December 2nd. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Robert W. Baird decreased their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $79.19.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.